The goal of this company, Gradient Therapy, is to develop therapeutics for the treatment of Inflammatory Bowel Disease (IBD).
The aim i s to formulate compounds from a class of chemotactic peptides, to be delivered rectally to the GI tract and to be tested in animals. A rabbit colitis model is to be used in the proposal. Treatment groups will be assessed for clinical response, with histologic and biochemical parameters used. The goal is to obtain a specific peptide and dose for a Phase I human trial and to produce adequate stable quantities of the test compound.
The
of the chemotactic peptides is to treat the acute and chronic manifestations of Inflammatory Bowel Disease, specifically Crohn's Disease and ulcerative colitis.
